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Background
Biomarkers play different roles in trials, being accord-
ingly classified into ‘prognostic’, ‘predictive’, ‘surrogate’,
or combinations thereof. Knowledge of a biomarker’s
role enables focused testing in late Phase trials through
a better choice from available designs (e.g. ‘stratified’,
‘strategy’,a n d‘enrichment’). Preliminary studies can
inform a biomarker’s role and the relative value of mul-
tiple biomarkers.
Motivation
Here we consider the design of a preliminary study of
potentially predictive biomarkers in patients treated for
Psoriasis. A clinical researcher came for methodological
advice, bringing a related published study with exciting
results but of highly dubious quality. The objective was to
provide a design with better properties (less bias, high
power, low cost), allowing multiple biomarkers and their
combination to be assessed to inform any subsequent trial.
Methods
Prior preferences, agreed by the researcher, were for a
prospective design, control groups, and power-based
sample size calculation. A formal 10-minute presenta-
tion to the full team was required to explain pros and
cons of an adaptive element (two recruitment stages) to
the design. Power was assessed through simulation in R-
software using Fisher’s method, involving the product of
stage p-values.
Results
Effect size was defined in terms of the correlation
between treatment response over time and a biomarker.
Under a non-adaptive design, an R-squared of 20%
could be detected with 90% power, 5% significance level,
with 49 patients, with all 17 expensive biomarkers mea-
sured. The adaptive design offered an interesting alter-
native, employing p>0.3 to discontinue with biomarkers
quarter-way through recruitment, requiring 24+72=96
patients. This offers more patients to develop a combi-
nation from an enriched biomarker set guaranteed to
include the best five performers from stage one. The
proportion of biomarkers expected to discontinue, con-
ditional on underlying effect size, was considered
graphically.
Conclusions
Incorporating methodological improvements into study
designs requires understanding of methodology and col-
laborators. The cost-efficient two-stage design is an
improvement on the related published study, and we
outline further analysis-stage developments: reducing
bias in estimates and providing valid confidence inter-
vals and error rates [1,2]. The study proposal is cur-
rently going through ethics.
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